Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma.
|
|
- Shanna Rogers
- 5 years ago
- Views:
Transcription
1 Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma.
2 Introduction to Mepact (mifamurtide) Mepact, also known as mifamurtide, is a medicine used to treat bone cancer (also called osteosarcoma) in children, adolescents and young adults. You have just been prescribed mifamurtide to help treat your bone cancer. Mifamurtide contains a special substance that stimulates the immune system (the part of the body that defends itself against germs and microorganisms) to help your body kill cancer cells. Understanding the benefits of mifamurtide This leaflet is designed to help you better understand the benefits of mifamurtide, and what to expect from it, so you will be better able to cope with your treatment and get on with your life. Please read the leaflet carefully. If you have any questions that are not covered in these pages, or would simply like to know a bit more about taking mifamurtide, or how mifamurtide can help you, don t hesitate to ask your doctor or nurse. Why do I have to take another treatment? You will already have undergone a number of tests for your disease, and will have experienced a combination of different treatments, among them chemotherapy, surgery, and maybe even radiotherapy. All this may have been extremely difficult and distressing for you, and you might be wondering why you need to take another treatment. This is because your doctor believes that mifamurtide may make a significant difference to your treatment outcome and your subsequent well-being.
3 When is mifamurtide used? Mifamurtide is used after you ve had surgery to remove your cancer. Mifamurtide is used together with chemotherapy to kill any remaining cancer cells that might still be around in your body, to reduce the risk of your cancer coming back. Mifamurtide and chemotherapy You will already be familiar with chemotherapy as it will have been given to you to shrink your cancer before it was removed by surgery. You will also be familiar with the kind of side effects that chemotherapy can cause. Mifamurtide is designed to work hand-in-hand with your chemotherapy, and there is no evidence of mifamurtide interfering with the effects of chemotherapy. The only additional side effects that might occur with mifamurtide tend to be mild to moderate in nature and these side effects are dealt with in the next section. If you do have any concerns about your next round of chemotherapy, talk to your doctor or nurse about it. What are the benefits of treatment with mifamurtide? The active substance in Mepact, mifamurtide, is an immunomodulator (i.e. changes the immune system). It works by activating macrophages and monocytes (types of white blood cell that form part of the immune system). The precise way that mifamurtide works in osteosarcoma is not fully understood, but it is thought to cause the white blood cells to release chemicals that kill the cancerous cells. When used with other anti-cancer medicines, mifamurtide increased how long patients survived without their disease coming back: 68% of the patients receiving mifamurtide (231 out of 338) survived without the disease coming back, compared with 61% of the patients who did not receive it (207 out of 340). The chances of surviving was improved in patients receiving Mepact.
4 Will I get any side effects from mifamurtide? Like all medicines, mifamurtide can cause side effects, although not everybody will get them. Chills, fever and feelings of nausea and tiredness are the most common side effects that may result from mifamurtide treatment. Other side effects that you may commonly experience include dizziness, vomiting, diarrahoea, constipation, headache, pain, sweating and a rapid heart beat. The good news is, these side effects are usually mild or moderate in nature, they do not last long, and they can usually be treated with simple medication by your doctor, e.g. with paracetamol for a fever. If you want to know more about mifamurtide s possible side effects, a full list of these is included on the leaflet that comes with your medicine. Contact your doctor immediately: - If you continue to have a fever or chills more than 8 hours after you take have received mifamurtide, as this could mean you have an infection - If you experience any breathing problems (like wheezing) - If you get any kind of a rash - If you experience any stomach problems - If you are concerned about any other symptoms Where will mifamurtide be given to me? Mifamurtide will be given to you in hospital, by a doctor or nurse, at the same time as your chemotherapy. As your treatment continues, it may well be given to you as an outpatient, which means visiting the hospital only at certain appointed times. How is mifamurtide given and will it hurt? Mifamurtide is given to you intravenously. This means it is given directly into your vein by infusion. As with other procedures involving injections, this may hurt a little at the point where the needle pierces the skin, but afterwards any pain should fade away. As is sometimes the case with injections, the area where the needle has penetrated the skin might be a bit sore afterwards.
5 How long will the mifamurtide infusion last? The whole procedure of giving mifamurtide usually lasts about one hour, with the doctor or nurse monitoring you during that time. How often will I receive mifamurtide? Mifamurtide will be given to you twice a week, at least 3 days apart, for a period of 12 weeks. Mifamurtide will then be given once weekly for another 24 weeks. That s a total of 48 infusions over a period of 36 weeks. Counselling Having bone cancer is probably one of the most difficult things a young person will have to go through in their lives. As well as the shock of having the disease and the disruption it will have caused to your social life and schooling, the pain and discomfort of the surgery and chemotherapy will have been hard to cope with. Many different emotions may affect you. Anger, guilt, anxiety and fear are some of the most common feelings people in your situation have experienced. You may find you are restless and unable to sleep, or you may be depressed or have feelings of hopelessness. These are all perfectly normal reactions to your situation, but it is often difficult and distressing to share or admit to them. Because of this, you may feel that you want to talk to someone about your situation, or your feelings. As well as friends and family, there are qualified people available to help you. Some hospitals have their own emotional support services with specially-trained staff. Some of the nurses on the ward will have received training in counselling, but you may feel more comfortable talking to a counsellor outside the hospital environment. On a more practical level, while most people recover well after surgery and are able to move around quite quickly, some people take longer and may need extra help. Before you go home the medical staff will talk to you about your home situation. If you live alone or have several stairs to climb, you may need some help at home. Children and teenagers may also worry about falling behind at school. In some cases, home tutoring can often be arranged with the local education authority. The person responsible for your schooling while you are in hospital may be able to organise this for you. At the back of this leaflet are some organisations that you can contact for extra help, support and general advice.
6 Mifamurtide and adult patients Mifamurtide is given to children (2 years upwards), adolescents and young adults. The information already covered in this leaflet applies to all patients in this category. There are some issues, however, that apply only to adult patients, and these are covered in the following sections.
7 Driving or using machines No studies of the effects of mifamurtide on ability to drive or use machines have been performed. However, some side effects of mifamurtide treatment (such as dizziness, vertigo, fatigue and blurred vision) may have an effect on your ability to drive and use machines. Pregnancy and breastfeeding Because there are no data concerning the use of mifamurtide in pregnant patients, mifamurtide should not be used during pregnancy, nor in women not using effective contraception. You should always use effective contraception if you are being treated with mifamurtide, and it is important to tell your doctor if you think you may be pregnant, or are planning to get pregnant. For women breastfeeding, again there are no data as to whether mifamurtide is excreted in human milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of mifamurtide therapy to you. This is an issue best discussed with your doctor or nurse. Fertility No dedicated fertility studies have been conducted with mifamurtide. If you have any questions regarding any other aspect of your health that may be affected please consult your doctor or nurse. If you have any further questions not covered in this leaflet, ask your doctor or nurse. Also, if any of the side effects already mentioned gets serious, or if you experience any side effects not listed here or in the package leaflet, please tell your doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine.
8 Some useful organisations Bone Cancer Research Trust BCRT is a charity dedicated to improving outcomes for people affected by primary bone cancer, and they achieve this through research, awareness, information and support. They enable patients and their families to connect with each other and know that they are not alone. Website: Cancer52 An organisation that represents the less common cancers, giving member charities and those they represent a more powerful voice and the driving force of a larger group, as well as listening to the community and sharing information and experience. Website: CLIC Sargent CLIC Sargent is the UK s leading cancer charity for children and young people, and their families. They provide clinical, practical and emotional support to help them cope with cancer and get the most out of life. They are there from diagnosis onwards and aim to help the whole family deal with the impact of cancer and its treatment. Website: Rarer Cancers Foundation Rarer Cancers Foundation draws together people with rare and less common cancers, giving them a bigger collective voice to exact better services, and enabling them to support one another. It makes health professionals aware of issues related to rarer cancers and works with the Government, the NHS and Primary Care Trusts/Health Boards to ensure that people with rarer cancers have access to the best possible services across the UK. Website: Sarcoma UK Sarcoma UK is the only cancer charity in the UK focusing on all types of sarcoma. Sarcoma UK s mission is to increase knowledge and awareness of sarcoma through ground-breaking programmes that inspire involvement and transform the landscape for everyone affected by sarcoma. They initiate change to raise sarcoma awareness and improve standards of treatment and care, seek answers through research and provide support and information for the sarcoma community. Website: Teenage Cancer Trust Teenage Cancer Trust is the only UK charity dedicated to improving the quality of life and chances of survival for young people with cancer aged 13 to 24. Teenage Cancer Trust funds and builds specialist units in NHS hospitals and provides dedicated staff, bringing young people together so they can be treated by teenage cancer experts in the best place for them. Teenage Cancer Trust also educates young people in schools about cancer to help improve the speed and quality of diagnosis. Website: Other useful contacts Date of preparation: February 2014 ME110112a(1)
Privigen solution for infusion
Privigen solution for infusion Haematology Patient Information What is is Privigen? Privigen? Privigen belongs in a class of medicines called human normal immunoglobins. Immunoglobulins are also called
More informationYoung Adult Cancer Service in south-east London
Young Adult Cancer Service in south-east London Contents p.3 About our service p.5 Meet the young adult cancer team p.12 Peer support p.12 Young adult research p.13 Useful web links p.14 Notes p.16 Contact
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.
New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic
More informationThe transition to parenthood, mood changes, postnatal depression and post traumatic stress disorder
The transition to parenthood, mood changes, postnatal depression and post traumatic stress disorder A Parent Information Leaflet Contents The transition to parenthood 3 What are the Baby Blues? 3 What
More informationTraztuzumab (Herceptin)
Traztuzumab (Herceptin) Information for patients Chemotherapy Name Hospital No Your consultant is Important Advice Always carry your chemotherapy alert card. It is important that you know what to do if
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES Lubiprostone This medicine is subject to additional monitoring. This will allow quick identification of new
More informationSome general information on hepatitis A infection is given at the end of this leaflet.
Package Leaflet: Information for the User Havrix Monodose Vaccine Suspension for injection in a pre-filled syringe Hepatitis A (inactivated) vaccine (adsorbed) Read all of this leaflet carefully before
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Pregabalin For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationPentostatin (Nipent )
Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin
PACKAGE LEAFLET: INFORMATION FOR THE USER XIFAXANTA 200 mg film-coated tablets Rifaximin Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Carbamazepine For the Treatment of Pain This information is not intended to replace your doctor s
More informationDepartment of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12
Department of Clinical Haematology Chemotherapy Information for patients Page 1 of 12 You may find this booklet helpful if you or someone close to you is going to have chemotherapy. It explains: what chemotherapy
More informationwas proven to help people live longer1 BLINCYTO A guide for patients and caregivers
In a clinical trial for people with a certain kind of ALL whose cancer has returned or didn t respond to treatment 1 BLINCYTO was proven to help people live longer1 In a study of 405 adults with ALL, 271
More informationDrug information. Belimumab BELIMUMAB. is used to treat lupus (SLE) Helpline
Drug information Belimumab BELIMUMAB is used to treat lupus (SLE) Helpline 0800 5200 520 1 Introduction Belimumab is a drug that can help prevent your condition causing damage to your body. You can discuss
More informationPerjeta Contains the active ingredient pertuzumab (rch)
Perjeta Contains the active ingredient pertuzumab (rch) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Perjeta. It does not contain all the available
More informationUniversity College Hospital
University College Hospital Haematology Psychology and Counselling Service (for patients with blood cancer, red cell disorders and other non-cancer conditions) 1 If you would like this document in another
More informationBLINCYTO can eliminate detectable traces of cancer 1
For people* with B-cell precursor ALL who are MRD+, 1 BLINCYTO can eliminate detectable traces of cancer 1 In a study of 86 adults with MRD+ B-cell precursor ALL, BLINCYTO removed detectable traces of
More informationFor the Patient: ULUAVPMTN
ABOUT THIS MEDICATION For the Patient: ULUAVPMTN Other Names: Maintenance Therapy of Advanced n-small Cell Lung Cancer (NSCLC) with Pemetrexed U = Undesignated (requires special approval) LU = LUng AV
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: BEP (5 day) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationMEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use
MEDICATION GUIDE BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use Read this Medication Guide before you start receiving BENLYSTA and before each treatment. There may be new information.
More informationThis leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.
Consumer Medicine Information HERCEPTIN SC Trastuzumab 600 mg/5 ml solution for subcutaneous injection What is in this leaflet This leaflet answers some common questions about HERCEPTIN SC. It does not
More informationNHS breast screening Helping you decide
NHS breast screening Helping you decide 1 What is breast cancer? 2 What is breast screening? 3 Breast screening results 6 Making a choice the possible benefits 9 and risks of breast screening What are
More informationPATIENT SURVEY FOR ADMINISTRATIVE USE ONLY. TO BE COMPLETED BY STUDY COORDINATOR.
PATIENT SURVEY FOR ADMINISTRATIVE USE ONLY. TO BE COMPLETED BY STUDY COORDINATOR. DATE OF VISIT: / / PATIENT ID: REGULAR PROVIDER: SITE OF VISIT: Cleveland Houston Manhattan Pittsburgh Thank you for agreeing
More informationPackage leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)
Package leaflet: Information for the user Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Read all of this leaflet carefully before you start taking this medicine because
More informationPackage Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets
PACKAGE LEAFLET Package Leaflet: Information for the user Methocarbamol 750mg Film-Coated Tablets Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationFor the Patient: LUAVPEM
For the Patient: LUAVPEM Other Names: Second-Line Treatment Of Advanced Non- Small Cell Lung Cancer (NSCLC) With Pemetrexed LU = LUng AV = AdVanced PEM = PEMetrexed ABOUT THIS MEDICATION What is this drug
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ILAXTEN 20 MG TABLETS bilastine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationRANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationoffers the possibility of a longer life 1 BLINCYTO A guide for patients and caregivers
In a study of 405 adults with Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, 271 were treated with BLINCYTO and 134 with chemotherapy. The adults
More informationTuscarawas County Health Department. Vivitrol Treatment Consent
Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide
More informationRituximab treatment in autoimmune blistering diseases
Rituximab treatment in autoimmune blistering diseases This leaflet explains more about having treatment with the medicine rituximab for an autoimmune blistering disease. It includes information about the
More informationREMAINING RESILIENT AFTER TRAUMATIC EVENTS
REMAINING RESILIENT AFTER TRAUMATIC EVENTS www.humanrightsatsea.org A post incident guide for you, your family and friends SUPPORTED BY REMAINING RESILIENT AFTER TRAUMATIC EVENTS A post incident guide
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium
PACKAGE LEAFLET: INFORMATION FOR THE USER Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Oxaliplatin- Fluorouracil (FOLFOX) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationA Patient Information Guide My Guide to HCV treatment and care. Helpful information for patients who have been prescribed MAVIRET
A Patient Information Guide My Guide to HCV treatment and care Helpful information for patients who have been prescribed MAVIRET The information in this booklet does not replace the Patient Information
More informationIf you have any concerns about using this medicine, ask your doctor or pharmacist.
Consumer Medicine Information Ocrevus Ocrelizumab 300 mg in 10 ml concentrate for solution for infusion What is in this leaflet Please read this leaflet carefully before you start using Ocrevus. This leaflet
More informationNHS SERVICES TO MEET YOUR NEEDS THE STANDARDS OF CARE YOU CAN EXPECT
NHS SERVICES TO MEET YOUR NEEDS Meeting these unique needs requires special knowledge and skills, so NHS England has stated that there should be cancer services especially for teenagers and young adults
More informationA N I N T R O D U C T I O N T O S T R E S S, A N X I E T Y A N D D E P R E S S I O N F O R M A N A G E R S K A T H C H E E R
A N I N T R O D U C T I O N T O S T R E S S, A N X I E T Y A N D D E P R E S S I O N F O R M A N A G E R S K A T H C H E E R Learning Outcomes Mental health facts and figures Greater understanding of stress,
More informationYour treatment with XELJANZ
Your treatment with XELJANZ (tofacitinib citrate) THIS BROCHURE HAS BEEN PRODUCED FOR PATIENTS WHO HAVE BEEN PRESCRIBED XELJANZ. BEFORE USING XELJANZ, PLEASE REVIEW THE PACKAGE LEAFLET FOR THIS MEDICINAL
More informationPATIENT INFORMATION BOOKLET
PATIENT INFORMATION BOOKLET GETTING STARTED WITH YOUR MEDICINES TIVICAY (dolutegravir) + lamivudine Tivicay is subject to additional monitoring. This will allow quick identification of new safety information.
More informationAfter an Accident or Trauma. A leaflet for patients who have been involved in an accident or traumatic event.
After an Accident or Trauma A leaflet for patients who have been involved in an accident or traumatic event. Traumatic experiences such as accidents are, of course, very distressing to those involved.
More informationPackage leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine
Package leaflet: Information for the patient Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine Read all of this leaflet carefully before you start taking
More informationFor the Patient: LUAVPG (Carboplatin Option)
For the Patient: LUAVPG (Carboplatin Option) Other Names: Treatment of Advanced n-small Cell Lung Cancer with Carboplatin and Gemcitabine LU = LUng AV = AdVanced PG = CarboPlatin, Gemcitabine ABOUT THIS
More informationInformation for patients having radiotherapy to the whole brain
Information for patients having radiotherapy to the whole brain Introduction This leaflet is for people who have been recommended treatment with a short course of radiotherapy to the brain. It is intended
More informationFor the Patient: USMAVNIV
For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab
More informationPatient guide to Capecitabine chemotherapy with radiotherapy for rectal cancer
Patient Name: Patient guide to chemotherapy with radiotherapy for rectal cancer Chemotherapy This guide should only be given to patients who have been prescribed capecitabine chemotherapy in conjunction
More informationBrentuximab vedotin. Brentuximab vedotin
Brentuximab vedotin Brentuximab vedotin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-Oxaliplatin- Fluorouracil (FLOT) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other
More informationPackage Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate)
Novartis (logo) Package Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate) Read all of this leaflet carefully before you start taking this medicine
More informationVentolin Injection 500 micrograms/ml salbutamol sulfate
Package leaflet: Information for the user Ventolin Injection 500 micrograms/ml salbutamol sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationFor the Patient: ULUAVPMB
For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT
More informationPemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)
Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet
More informationPackage leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid
Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important information
More informationPackage leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone
Package leaflet: Information for the patient Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone Read all of this leaflet carefully before you start taking this
More informationfor the grieving process How to cope as your loved one nears the end stages of IPF
Preparing yourself for the grieving process How to cope as your loved one nears the end stages of IPF 3 As your loved one nears the end stages of IPF, it s important that you be there for him or her as
More informationPain relief after caesarean section. Information for patients Royal Hallamshire Hospital, Jessop Wing
Pain relief after caesarean section Information for patients Royal Hallamshire Hospital, Jessop Wing Pain relief in the postnatal period Introduction This information leaflet has been written to give you
More informationCare and support. for younger women with breast cancer. The breast cancer support charity
Care and support for younger women with breast cancer The breast cancer support charity When you re young, breast cancer is often the last thing you expect to have to think about. A diagnosis may feel
More informationMycamine Micafungin (as sodium)
Mycamine Micafungin (as sodium) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Mycamine. It does not contain all the available information. It does
More informationPackage Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron
Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains
More informationNUCALA. mepolizumab. Patient Support
NUCALA mepolizumab Patient Support This booklet has been developed by GSK UK/NLA/0007/15(1) Date of preparation: November 2016 INTRODUCTION This informative guide is for people who have been prescribed
More informationPackage leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)
Package leaflet: Information for the patient Loratadine 10 mg Tablets (loratadine) Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationEmotional impact of sight loss
Emotional impact of sight loss The biggest cause of sight loss in this country is macular disease. Coping with your emotions after being diagnosed can be difficult. No one need face macular degeneration
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationPackage leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPackage leaflet: Information for the user. Cyclizine Lactate 50 mg/ml Injection
Package leaflet: Information for the user Cyclizine Lactate 50 mg/ml Injection Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Carboplatin-Etoposide PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationNorthern Ireland breast screening. Helping you decide
Northern Ireland breast screening Helping you decide What is breast cancer? 4 What is breast screening? 5 Breast screening results 8 Making a choice the possible benefits 11 and risks of breast screening
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: FEC-P PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE
More informationObinutuzumab (lymphoma) Obinutuzumab (lymphoma)
Obinutuzumab (lymphoma) Obinutuzumab (lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of this treatment vary: for some people, this immune therapy may reduce
More informationEloxatin Oxaliplatin concentrated solution for injection
Eloxatin Oxaliplatin concentrated solution for injection Consumer Medicine Information Please read this leaflet before you are given this medicine. What is in this leaflet This leaflet answers some common
More informationPackage leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin
Package leaflet: Information for the patient Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase
Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new
More informationFor the Patient: LUSCTOP
ABOUT THIS MEDICATION For the Patient: LUSCTOP Other Names: Treatment of Recurrent Small Cell Lung Cancer (SCLC) with Topotecan LU = LUng SC = Small Cell TOP = TOPotecan What is this treatment used for?
More informationFor the Patient: LUAVPP (Carboplatin Option)
ABOUT THIS MEDICATION For the Patient: LUAVPP (Carboplatin Option) Other Names: Treatment of Advanced n-small Cell Lung Cancer with Carboplatin and Pemetrexed LU = LUng AV = AdVanced PP = CarboPlatin,
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationTocilizumab Tocilizumab
Drug information Tocilizumab Tocilizumab This leaflet provides information on tocilizumab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationRituximab FOR NEUROLOGICAL DISORDERS
InfoNeuro Montreal Neurological Institute and Hospital INFORMATION FOR PATIENTS Rituximab FOR NEUROLOGICAL DISORDERS Prepared by: Sylvia de Melo, Nurse Clinician, Neuro Day Center Consultants: Lucia Fabijan,
More informationPost-Traumatic Stress Disorder
Post-Traumatic Stress Disorder Teena Jain 2017 Post-Traumatic Stress Disorder What is post-traumatic stress disorder, or PTSD? PTSD is a disorder that some people develop after experiencing a shocking,
More informationRecovering from a difficult birth.
NHS Fife Department of Psychology Recovering from a difficult birth. Help Yourself @ moodcafe.co.uk Recovering from a difficult birth This leaflet aims to give you information about recovering from a difficult
More informationNorthern Ireland breast screening. Helping you decide
Northern Ireland breast screening Helping you decide 1 What is breast cancer? 4 What is breast screening? 5 Breast screening results 9 Making a choice the possible benefits and risks of breast screening
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pembrolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationHow is primary breast cancer treated? This booklet is for anyone who has primary breast cancer and wants to know more about how it is treated.
How is primary breast cancer treated? This booklet is for anyone who has primary breast cancer and wants to know more about how it is treated. How is primary breast cancer treated? Part 1 the treatment
More informationD-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin
Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using
More informationCOPING WITH LOSS AND GRIEF
COUNSELLING SERVICE 3994/02.18/RD COPING WITH LOSS AND GRIEF MIND MATTERS COPING WITH LOSS AND GRIEF WHAT IS GRIEF? Throughout our lives, we all have to face change and loss. Sometimes this involves a
More informationThe role of the Teenage & Young Adult (TYA) Cancer Care Team
Oxford University Hospitals NHS Trust The role of the Teenage & Young Adult (TYA) Cancer Care Team The role of the Teenage & Young Adult Cancer Care Team Introduction We know that this must be a very difficult
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationNon-epileptic attacks
Non-epileptic attacks A short guide for patients and families Information for patients Neurology Psychotherapy Service What are non-epileptic attacks? Non-epileptic attacks are episodes in which people
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER DYSPORT 500 units Powder for solution for injection Clostridium botulinum type A toxin-haemagglutinin complex Read all of this leaflet carefully, before you start
More informationPackage leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon
Package leaflet: Information for the user GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon Read all of this leaflet carefully before you are given this injection because it
More information2 What you need to know before you take Zantac
Package leaflet: Information for the user Zantac Tablets 150 mg and 300 mg ranitidine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More information